Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PrecipioPRPO -1.11%53 12-1 Month Momentum % is 71.22% as of Aug. 11, 2026. GuruFocus rates PRPO with a GF Score™ of 53/100 and a GF Value™ of $10.74 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Precipio ranks better than 89.67% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-11), Precipio's 12-1 Month Momentum % is 71.22%.
The industry rank for Precipio's 12-1 Month Momentum % or its related term are showing as below:
PRPO's 12-1 Month Momentum % is ranked better than 89.67% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -9.17
vs PRPO: 71.22
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Precipio 12-1 Month Momentum % Related Terms
PRPO vs IDXG, ADVB, BIOQ: 12-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, Precipio's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precipio 12-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Precipio's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Precipio's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precipio (PRPO) has a 12-1 Month Momentum % of 71.22% as of Aug. 11, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Precipio and its competitors. According to the industry distribution chart, Precipio ranks #22 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 10.3%.
Is Precipio's 12-1 Month Momentum % too high?
Precipio's current 12-1 Month Momentum % is 71.22%. Based on the distribution chart, Precipio ranks #22 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Precipio has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precipio's 12-1 Month Momentum % compare to IDXG and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, Precipio ranks #22 out of 213 companies for 12-1 Month Momentum %. This places Precipio in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 12-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Precipio and its competitors. Precipio's current 12-1 Month Momentum % is 71.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precipio stock overvalued right now?
Based on GuruFocus' analysis, Precipio (PRPO) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.74, compared to a current price of $22.35 — trading 108.1% above its estimated fair value. The current 12-1 Month Momentum % is 71.22%. Precipio's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Precipio (PRPO), the current 12-1 Month Momentum % is 71.22% as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precipio (PRPO) Overvalued in 2026?
Based on GuruFocus' analysis, Precipio stock appears to be overvalued.
The current stock price of $22.35 is trading 108.1% above its estimated GF Value™ of $10.74.
GuruFocus considers Precipio to be Significantly Overvalued.
Key valuation signals for PRPO:
12-1 Month Momentum %: 71.22%
GF Value™: $10.74 vs. price of $22.35 (108.1% above fair value)
No single metric tells the full story. See the PRPO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
53GF Score
Get the complete analysis for PRPO
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPO has been successfully added to your 
